The clinical efficacy of the anti-HER2 trastuzumab in patients with breast cancer and the anti-CD20 rituximab in B non-Hodgkin lymphoma (NHL) demonstrated for the first time that mAbs can be commercialized as powerful therapeutic agents in the fight against cancer [10,11]. This evidence concerns the gene ERBB2 and breast carcinoma.